Johnson & Johnson (JNJ) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Core Insights - The company is preparing for the potential launch of icotrokinra, a targeted oral peptide for psoriasis treatment, which is seen as a transformative next-generation therapy [1][2] - Icotrokinra is the only asset that offers a combination of complete skin clearance, favorable safety, and the convenience of a once-daily pill [1] - The development program for icotrokinra has been robust, supporting its position as a first-line systemic therapy for psoriasis based on large Phase III study data [2]